Speech Perception for ALS
Trial Summary
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Listener judgements of speech for ALS?
How does the speech perception treatment for ALS differ from other treatments?
What is the purpose of this trial?
In this study, we will evaluate how solo, naive listeners perceive the speech of people with amyotrophic lateral sclerosis (ALS) and age-matched speakers produced across interactive and non-interactive contexts with an unfamiliar, naive interlocutor.
Research Team
Jimin Lee, Ph.D.
Principal Investigator
The Pennsylvania State University
Navin Viswanathan, Ph.D.
Principal Investigator
The Pennsylvania State University
Anne Olmstead, Ph.D.
Principal Investigator
The Pennsylvania State University
Eligibility Criteria
This trial is for individuals with Motor Neuron Disease, specifically Amyotrophic Lateral Sclerosis (ALS). Participants should be able to produce speech and willing to interact in various tasks. The study seeks age-matched speakers as well.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Listeners participate in a remote, asynchronous session to evaluate recorded speech
Follow-up
Participants are monitored for any additional feedback or data collection post-intervention
Treatment Details
Interventions
- Listener judgements of speech
Find a Clinic Near You
Who Is Running the Clinical Trial?
Penn State University
Lead Sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator